trending Market Intelligence /marketintelligence/en/news-insights/trending/gtofwpim2ihrpdg-2vpjnq2 content esgSubNav
In This List

US FDA approves Abbott's new Xience stent system

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


US FDA approves Abbott's new Xience stent system

The U.S. Food and Drug Administration approved Abbott Laboratories' Xience Sierra, a version of the company's Xience everolimus-eluting coronary stent system.

The company said the new stents have a "thinner profile, increased flexibility, longer lengths, and small diameters," and are designed to treat complex blockages that now account for up to 70% of cases.

According to Abbott, more than 8 million people globally have received a Xience stent since its initial regulatory approvals in the EU in 2006 and in the U.S. in 2008. The company received regulatory approval for Xience Sierra in Japan in April 2018, and CE Mark in Europe in October 2017.